Health budget, connected care, and drug consumption sites
Official: Briefing on the National Emergency Strategic Stockpile (NESS)
The House of Commons Standing Committee on Health met to discuss health-related aspects of the 2025 budget and a proposed law to improve sharing of health information. The Minister of Health, Marjorie Michel, presented the government's plans, including investments in health infrastructure, research, and biomanufacturing. She highlighted a proposed law aimed at creating a more connected health care system, allowing for better access to personal health information for Canadians and health professionals. Committee members questioned the minister on various topics, including supervised drug consumption sites, the Canadian dental care plan, and vaccine production. Officials from Health Canada and related agencies were present to provide additional information and support to the minister.
During the meeting, Dan Mazier (Conservative) questioned the Minister about a supervised drug consumption site near a child care facility in Ottawa. He asked why the permit for the site was renewed despite safety concerns raised by law enforcement. The Minister defended the decision, stating that the approval process involves multiple factors and that Health Canada had worked with the site to implement stricter measures. Helena Jaczek (Liberal) inquired about the Canadian dental care plan, and the Minister reported that millions of Canadians have enrolled and received care, with a wide range of oral health professionals participating in the program. Maxime Blanchette-Joncas (Bloc Québécois) questioned the Minister about investments in health infrastructure and vaccine production, expressing concerns about the adequacy of funding and the lack of domestic vaccine production capacity.
Later in the meeting, committee members questioned Health Canada officials on topics such as age requirements at supervised consumption sites, funding for harm reduction programs, and the progress of the vaccine injury support program. Kendal Weber, Assistant Deputy Minister, clarified that Health Canada does not set age limits for access to supervised consumption sites and that the sites are intended to provide support and prevent overdoses. Nancy Hamzawi, President of the Public Health Agency of Canada, provided updates on the vaccine injury support program, noting that thousands of claims have been submitted and that payments have been made to eligible claimants. The committee also discussed a proposed law to amend the Human Pathogens and Toxins Act, with officials explaining that the changes are needed to address evolving biosecurity risks and strengthen oversight of the biomanufacturing sector.
Paul Hébert, President of the Canadian Institutes for Health Research, spoke about the potential of the connected care proposed law to improve health care delivery and support research and innovation. He emphasized the importance of data sharing and interoperability to enable better clinical trials, personalized treatment, and system planning. Kimby Barton, Director General of the Centre for Biosecurity, discussed the motivation behind the amendments to the Human Pathogens and Toxins Act, citing factors such as increased investment in biomanufacturing and an evolving threat landscape. The committee agreed to extend the deadline for public submissions on antimicrobial resistance to March 15, 2026.